In a report released today, Gil Blum from Needham reiterated a Buy rating on Celcuity (CELC - Research Report), with a price target of $25.00. The company's shares closed yesterday at $10.00.Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Geron, and Rocket Pharmaceuticals. According to TipRanks, Blum has an average return of -22.4% and a 29.02% success rate on recommended stocks. Celcuity has an analyst consensus of Moderate Buy, with a price target consensus of $25.00.See Insiders’ Hot Stocks on TipRanks >> Based on Celcuity's latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $9.
https://www.tipranks.com/news/blurbs/needham-sticks-to-its-buy-rating-for-celcuity-celc?utm_source=advfn.com&utm_medium=referral